Agents for inducing immunity specific to Sars-cov-2
The present invention relates to immunology, and describes an agent in liquid form for inducing specific immunity against SARS-CoV-2, containing a single active ingredient, comprising an expression vector of human adenovirus serotype 26 in which the E1 and E3 regions are deleted, the ORF6-Ad26 regio...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The present invention relates to immunology, and describes an agent in liquid form for inducing specific immunity against SARS-CoV-2, containing a single active ingredient, comprising an expression vector of human adenovirus serotype 26 in which the E1 and E3 regions are deleted, the ORF6-Ad26 region is replaced by ORF6-Ad5, and having an integrated expression cassette selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. In another variant, the reagent contains a single active ingredient comprising an expression vector of human adenovirus serotype 5 wherein E1 and E3 regions are deleted, and has an integrated expression cassette selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. In another variant, the agent contains a single active ingredient comprising an expression vector of simian adenovirus serotype 25 wherein E1 and E3 regions are deleted, and has an integrated expression cassette selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 2, SE |
---|